Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is developing two therapies targeting hematological malignancies, specifically, relapsed, and refractory non-Hodgkins lymphoma.
Website: tgtherapeutics.com



Growth: Bad revenue growth rate -50.0%, there is slowdown compared to average historical growth rates 70.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -4 014.3%. On average the margin is decreasing steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -3.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 799.5% higher than minimum and 26.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -192.1x by EV / Sales multiple

Key Financials (Download financials)

Ticker: TGTX
Share price, USD:  (-0.6%)33.64
year average price 27.80  


year start price 16.62 2024-05-11

min close price 15.81 2024-06-06

max close price 45.51 2025-04-30

current price 33.64 2025-05-10
Common stocks: 135 411 258

Dividend Yield:  0.0%
EV / Sales: 617.6x
Margin (EBITDA LTM / Revenue): -4 014.3%
Fundamental value created in LTM:
Market Cap ($m): 4 555
Net Debt ($m): -232
EV (Enterprise Value): 4 323
Price to Book: 23.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-05fool.com

Why TG Therapeutics Stock Was Tumbling Today

2025-05-05zacks.com

TG Therapeutics (TGTX) Lags Q1 Earnings Estimates

2025-04-30globenewswire.com

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

2025-04-10zacks.com

TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

2025-03-21investors.com

These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles

2025-03-17zacks.com

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

2025-03-14seekingalpha.com

TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials

2025-03-07fool.com

Why TG Therapeutics Stock Was Soaring This Week

2025-03-07globenewswire.com

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

2025-01-23seekingalpha.com

TG Therapeutics: Entering 2025 With Increased Investor Expectations
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TGTX TGTX TGTX TGTX TGTX TGTX TGTX TGTX TGTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-09 2024-05-06 2024-02-29 2023-11-06 2023-08-04 2023-05-08 2023-03-01 2022-11-09
acceptedDate 2024-11-07 16:33:58 2024-08-09 16:03:55 2024-05-06 16:59:11 2024-02-29 17:23:27 2023-11-06 17:01:09 2023-08-04 16:30:38 2023-05-08 07:59:32 2023-03-01 17:21:09 2022-11-09 16:30:43
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 84M 73M 63M 44M 166M 16M 8M 80 000 94 000
costOfRevenue 9M 8M 6M 8M 4M 2M 857 000 3000 2000
grossProfit 75M 65M 58M 36M 162M 14M 7M 77 000 92 000
grossProfitRatio 0.889 0.886 0.913 0.819 0.979 0.881 0.89 0.963 0.979
researchAndDevelopmentExpenses 20M 18M 33M 17M 12M 22M 14M 24M 18M
generalAndAdministrativeExpenses 42M 39M 35M 34M 36M 36M 30M 28M 18M
sellingAndMarketingExpenses 0 -72 000 -82 000 -3M -9M 0 0 -12M -7M
sellingGeneralAndAdministrativeExpenses 42M 39M 34M 31M 27M 36M 30M 28M 11M
otherExpenses 0 2M 880 000 890 000 9M 691 000 604 000 2M 7M
operatingExpenses 62M 56M 67M 49M 48M 59M 44M 52M 35M
costAndExpenses 71M 65M 73M 56M 51M 61M 45M 52M 35M
interestIncome 0 0 0 -10M 4M 4M 0 0 0
interestExpense 11M 4M 2M 2M 4M 4M 3M 3M 2M
depreciationAndAmortization 64 000 72 000 82 000 43 812 126 000 691 000 604 000 2M 851 000
ebitda 15M 11M -9M -12M 115M -44M -36M -50M -34M
ebitdaratio 0.18 0.121 -0.145 -0.282 0.692 -2.736 -4.663 -626.65 -362.894
operatingIncome 12M 9M -9M -12M 115M -45M -37M -52M -35M
operatingIncomeRatio 0.148 0.12 -0.146 -0.284 0.692 -2.779 -4.741 -650.775 -371.947
totalOtherIncomeExpensesNet -8M -2M -1M -2M -854 000 691 000 -2M -932 000 -855 000
incomeBeforeTax 4M 7M -11M -14M 114M -48M -39M -53M -36M
incomeBeforeTaxRatio 0.051 0.089 -0.168 -0.319 0.687 -2.962 -5.028 -662.425 -381.043
incomeTaxExpense 388 000 -328 000 29 000 390 000 -126 000 4M -604 000 930 000 855 000
netIncome 4M 7M -11M -14M 114M -48M -39M -54M -37M
netIncomeRatio 0.046 0.094 -0.169 -0.328 0.687 -2.962 -4.95 -674.05 -390.138
eps 0.027 0.048 -0.073 -0.1 0.8 -0.34 -0.28 -0.39 -0.27
epsdiluted 0.024 0.043 -0.073 -0.1 0.73 -0.34 -0.28 -0.39 -0.27
weightedAverageShsOut 145M 145M 146M 143M 143M 142M 140M 137M 135M
weightedAverageShsOutDil 161M 159M 146M 143M 156M 142M 140M 137M 135M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TGTX TGTX TGTX TGTX TGTX TGTX TGTX TGTX TGTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-09 2024-05-06 2024-02-29 2023-11-06 2023-08-04 2023-05-08 2023-03-01 2022-11-09
acceptedDate 2024-11-07 16:33:58 2024-08-09 16:03:55 2024-05-06 16:59:11 2024-02-29 17:23:27 2023-11-06 17:01:09 2023-08-04 16:30:38 2023-05-08 07:59:32 2023-03-01 17:21:09 2022-11-09 16:30:43
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 196M 83M 75M 93M 229M 97M 61M 102M 110M
shortTermInvestments 145M 134M 134M 125M 78M 48M 78M 59M 66M
cashAndShortTermInvestments 341M 217M 210M 218M 229M 145M 140M 174M 176M
netReceivables 116M 84M 65M 51M 39M 17M 9M 0 0
inventory 85M 81M 78M 40M 34M 30M 27M 0 0
otherCurrentAssets 33M 7M 8M 10M 17M 16M 45M 7M 7M
totalCurrentAssets 574M 389M 361M 318M 229M 145M 185M 168M 183M
propertyPlantEquipmentNet 7M 8M 8M 8M 8M 8M 9M 11M 9M
goodwill 0 0 799 000 799 000 799 000 799 000 799 000 799 000 799 000
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 799 000 799 000 799 000 799 000 799 000 799 000 799 000
longTermInvestments 1M 2M 3M 1M 1M 1M 0 12M 22M
taxAssets 0 0 -10M 0 -1M -1M 0 0 0
otherNonCurrentAssets 3M 2M 11M 1M 3M 3M 3M 1M 3M
totalNonCurrentAssets 12M 12M 13M 12M 12M 12M 13M 25M 35M
otherAssets 0 0 1 0 90M 64M 0 0 0
totalAssets 586M 401M 373M 330M 331M 221M 197M 194M 218M
accountPayables 0 0 87M 38M 40M 63M 0 42M 30M
shortTermDebt 1M 3M 1M 1M 1M 2M 2M 2M 2M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 9M 3M 3M 300 000 7M 229 000 267 000 305 000 343 000
otherCurrentLiabilities 115M 103M 8M 14M 10M 8M 61M 9M 5M
totalCurrentLiabilities 125M 109M 100M 54M 58M 73M 63M 53M 36M
longTermDebt 253M 111M 101M 100M 10M 10M 10M 81M 11M
deferredRevenueNonCurrent 16M 4M 3M 6M 190 000 229 000 267 000 305 000 343 000
deferredTaxLiabilitiesNonCurrent 0 -94M 6M 0 0 -229 000 0 -82M 0
otherNonCurrentLiabilities 0 0 3M 9M 99M 98M 97M 82M 49M
totalNonCurrentLiabilities 269M 115M 114M 115M 109M 108M 107M 82M 81M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 10M 10M 9M 9M 11M 11M 12M 12M 12M
totalLiabilities 394M 224M 213M 169M 166M 180M 170M 135M 117M
preferredStock 0 1 379M 0 1 0 0 0 0 0
commonStock 156 000 155 000 155 000 151 000 151 000 151 000 149 000 146 000 145 000
retainedEarnings -1 553M -1 556M -1 525M -1 514M -1 500M -1 614M -1 566M -1 527M -1 474M
accumulatedOtherComprehensiveIncomeLoss 0 160M -0 0 -0 0 0 0 0
othertotalStockholdersEquity 1 745M 1 734M 1 685M 1 675M -151 000 -151 000 -149 000 -146 000 1 574M
totalStockholdersEquity 192M 178M 160M 161M -1 500M -1 614M -1 566M -1 527M 100M
totalEquity 192M 178M 160M 161M -1 500M -1 614M -1 566M -1 527M 100M
totalLiabilitiesAndStockholdersEquity 586M 401M 373M 330M -1 334M -1 433M -1 396M -1 392M 218M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 586M 401M 373M 330M -1 334M -1 433M -1 396M -1 392M 218M
totalInvestments 146M 137M 137M 126M 78M 48M 78M 72M 88M
totalDebt 254M 113M 112M 111M 11M 11M 12M 83M 12M
netDebt 58M 30M 36M 18M -218M -86M -50M -19M -98M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TGTX TGTX TGTX TGTX TGTX TGTX TGTX TGTX TGTX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-09 2024-05-06 2024-02-29 2023-11-06 2023-08-04 2023-05-08 2023-03-01 2022-11-09
acceptedDate 2024-11-07 16:33:58 2024-08-09 16:03:55 2024-05-06 16:59:11 2024-02-29 17:23:27 2023-11-06 17:01:09 2023-08-04 16:30:38 2023-05-08 07:59:32 2023-03-01 17:21:09 2022-11-09 16:30:43
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 4M 7M -11M -14M 114M -48M -39M -53M -36M
depreciationAndAmortization -5M 72 000 82 000 91 000 126 000 85 000 121 000 126 000 129 000
deferredIncomeTax 0 0 0 -24M 15M -186 000 0 0 0
stockBasedCompensation 12M 9M 9M 9M 9M 13M 7M 11M 7M
changeInWorkingCapital 17M -11M -6M -8M -40M -8M -28M 17M -7M
accountsReceivables -32M -19M -14M -12M -22M -9M -9M 0 88 000
inventory -3M -3M -37M -6M -3M -2M -27M 0 0
accountsPayables 12M 9M 40M 3M -22M 3M 10M 16M -27M
otherWorkingCapital 40M 2M 5M 7M 7M -38 000 -3M 584 000 20M
otherNonCashItems -39M 22M 19M 24M -15M 1M 710 000 937 000 2M
netCashProvidedByOperatingActivities -12M 6M -8M -13M 84M -42M -60M -24M -34M
investmentsInPropertyPlantAndEquipment -24 000 0 0 0 0 0 0 -3000 -4000
acquisitionsNet 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 152M -70M -83M -68M -56M 0 -22M -4M -31M
salesMaturitiesOfInvestments -145M 71M 73M 24M 26M 31M 16M 20M 28M
otherInvestingActivites -17M 0 -9M -45M -30M 0 0 0 0
netCashUsedForInvestingActivites -9M 2M -9M -45M -30M 31M -6M 16M -3M
debtRepayment 137M 0 0 -25M 0 0 0 0 0
commonStockIssued -145 000 135 000 10000 -1000 1000 47M 0 0 0
commonStockRepurchased 0 0 0 -1000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -659 000 135 000 10000 -420 000 420 000 0 25M 49 000 275 000
netCashUsedProvidedByFinancingActivities 134M 135 000 10000 -1000 421 000 47M 25M 49 000 275 000
effectOfForexChangesOnCash 0 0 0 -3000 0 0 0 0 0
netChangeInCash 114M 7M -17M -58M 54M 36M -41M -8M -37M
cashAtEndOfPeriod 197M 83M 75M 93M 152M 98M 63M 104M 111M
cashAtBeginningOfPeriod 83M 75M 93M 151M 98M 63M 104M 111M 148M
operatingCashFlow -12M 6M -8M -13M 84M -42M -60M -24M -34M
capitalExpenditure -24 000 0 0 0 0 0 0 -3000 -4000
freeCashFlow -12M 6M -8M -13M 84M -42M -60M -24M -34M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-04 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-05 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-01 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-12 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)

Press-releases

Show financial reports only

2024-11-04 12:00 ET
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
2024-11-01 12:06 ET
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
2024-09-18 11:15 ET
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
2024-09-18 11:00 ET
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
2024-09-05 11:30 ET
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2024-08-06 13:01 ET
HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics
2024-08-06 11:00 ET
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
2024-08-05 11:30 ET
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
2024-06-07 11:50 ET
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-06-03 11:30 ET
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
2024-05-28 11:30 ET
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
2024-05-01 11:00 ET
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
2024-04-30 20:55 ET
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
2024-04-18 11:30 ET
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
2024-04-18 11:00 ET
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
2024-04-15 11:30 ET
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
2024-03-08 12:30 ET
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
2024-03-01 12:30 ET
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2024-02-28 12:00 ET
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
2024-02-27 12:30 ET
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
2024-02-26 12:00 ET
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
2024-02-23 12:30 ET
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
2024-02-20 12:30 ET
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2024-02-12 12:00 ET
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
2024-01-10 12:00 ET
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
2024-01-05 12:30 ET
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-27 12:30 ET
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-11-03 11:30 ET
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
2023-11-01 11:30 ET
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-10-30 11:30 ET
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
2023-10-12 15:00 ET
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2023-10-11 14:30 ET
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2023-10-02 11:30 ET
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2023-09-22 11:30 ET
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
2023-09-07 11:30 ET
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-01 11:15 ET
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-08-01 11:00 ET
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
2023-07-31 12:30 ET
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
2023-06-05 11:30 ET
TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
2023-06-01 13:15 ET
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
2023-05-31 11:30 ET
TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
2023-05-04 11:30 ET
TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
2023-05-01 11:30 ET
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
2023-04-28 20:30 ET
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
2023-04-27 11:30 ET
TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
2023-04-25 12:00 ET
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
2023-03-31 11:30 ET
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
2023-03-03 13:30 ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
2023-02-28 12:30 ET
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
2023-02-24 12:30 ET
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
2023-02-24 12:00 ET
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2023-02-14 12:30 ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2023-01-26 12:00 ET
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
2023-01-06 12:30 ET
TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-28 18:48 ET
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
2022-11-10 12:30 ET
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
2022-11-08 12:30 ET
TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update
2022-10-26 11:30 ET
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
2022-10-13 11:30 ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
2022-09-09 11:30 ET
TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
2022-08-25 11:30 ET
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
2022-08-08 11:30 ET
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
2022-08-05 11:30 ET
TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update
2022-06-27 11:30 ET
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
2022-06-03 11:30 ET
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
2022-05-31 11:30 ET
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
2022-05-26 11:30 ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
2022-05-20 11:30 ET
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
2022-04-26 11:30 ET
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
2022-04-15 12:30 ET
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
2022-04-06 11:30 ET
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
2022-04-04 11:44 ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
2022-03-10 13:15 ET
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
2022-03-04 12:30 ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
2022-03-03 13:00 ET
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL
2022-03-01 12:30 ET
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
2022-02-25 12:30 ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2022-02-24 12:30 ET
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
2022-02-15 12:30 ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2022-01-24 12:30 ET
TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
2022-01-05 12:30 ET
TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
2022-01-04 12:30 ET
TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million
2021-12-14 12:30 ET
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-12-14 12:15 ET
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
2021-12-13 12:30 ET
TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-12-10 12:30 ET
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting
2021-11-30 12:30 ET
TG Therapeutics Provides Regulatory Update
2021-11-15 12:30 ET
TG Therapeutics to Participate in the Jefferies London Healthcare Conference
2021-11-09 12:30 ET
TG Therapeutics to Participate in the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series
2021-11-04 13:34 ET
TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-11-04 11:00 ET
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
2021-11-01 11:30 ET
TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update
2021-10-14 14:45 ET
TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
2021-09-30 11:30 ET
TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
2021-09-29 11:30 ET
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
2021-09-23 12:00 ET
TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances
2021-09-23 11:30 ET
TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
2021-09-20 11:30 ET
TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
2021-09-13 13:21 ET
TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
2021-09-09 13:00 ET
TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-30 11:30 ET
TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
2021-08-02 11:00 ET
TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
2021-07-28 11:30 ET
TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business Update
2021-07-09 11:30 ET
TG Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
2021-06-29 11:30 ET
TG Therapeutics Mourns the Loss of Board Member, William J. Kennedy, PhD
2021-06-18 18:00 ET
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
2021-06-18 11:35 ET
TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma
2021-06-11 11:00 ET
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress
2021-06-09 11:00 ET
TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma
2021-06-04 13:00 ET
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting
2021-05-27 11:30 ET
TG Therapeutics to Present at Upcoming Investor Conferences
2021-05-25 11:00 ET
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2021-05-13 11:30 ET
TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
2021-05-10 11:00 ET
TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
2021-05-06 11:30 ET
TG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business Update
2021-04-26 11:30 ET
TG Therapeutics to Participate in the B. Riley Securities Neuroscience Conference
2021-04-26 11:00 ET
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
2021-04-25 23:10 ET
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
2021-04-21 11:00 ET
TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and Venetoclax
2021-04-16 11:30 ET
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
2021-04-15 20:00 ET
TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
2021-03-29 11:42 ET
TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia
2021-03-09 12:30 ET
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology
2021-03-04 21:30 ET
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting
2021-03-04 12:30 ET
TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
2021-03-02 12:00 ET
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results
2021-02-26 12:30 ET
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update
2021-02-23 12:30 ET
TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology
2021-02-09 04:45 ET
Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL
2021-02-05 18:54 ET
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)
2021-01-15 12:00 ET
TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference
2021-01-08 12:00 ET
TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-15 00:51 ET
TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
2020-12-14 12:30 ET
TG Therapeutics Announces Proposed Public Offering of Common Stock
2020-12-10 12:12 ET
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
2020-12-07 15:15 ET
TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting
2020-12-07 15:00 ET
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting
2020-12-03 12:00 ET
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
2020-12-02 12:15 ET
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in Blood
2020-12-01 12:00 ET
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
2020-11-30 12:00 ET
TG Therapeutics to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
2020-11-13 12:00 ET
TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
2020-11-09 21:15 ET
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
2020-11-04 16:45 ET
TG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
2020-11-02 12:00 ET
TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
2020-10-21 11:30 ET
TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
2020-09-09 13:17 ET
TG Therapeutics to Present at Upcoming Investor Conferences
2020-08-13 11:00 ET
TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma
2020-08-10 11:00 ET
TG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
2020-08-06 11:30 ET
TG Therapeutics to Host Conference Call on Second Quarter 2020 Financial Results and Business Update
2020-07-08 11:00 ET
TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib
2020-06-22 13:00 ET
TG Therapeutics Announces Preclinical Data Presentation at the 2020 American Association for Cancer Research Annual Meeting
2020-06-17 11:00 ET
TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
2020-06-16 11:00 ET
TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation Conference
2020-06-12 11:00 ET
TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress
2020-06-09 11:00 ET
TG Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
2020-06-02 11:00 ET
TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference
2020-05-29 12:15 ET
TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting
2020-05-15 11:00 ET
TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting
2020-05-15 02:08 ET
TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
2020-05-14 20:01 ET
TG Therapeutics Announces Proposed Public Offering of Common Stock
2020-05-14 13:27 ET
TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
2020-05-11 20:00 ET
TG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
2020-05-08 11:00 ET
TG Therapeutics Strengthens Executive Team with the Addition of Owen A. O’Connor, MD, PhD, as Chief Scientific Officer
2020-05-06 11:00 ET
TG Therapeutics Raises Approximately $60 Million in Gross Proceeds Through its At-the-Market Facility
2020-05-05 11:00 ET
TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia
2020-05-01 11:30 ET
TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
2020-04-29 11:20 ET
TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD
2020-03-09 12:00 ET
TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
2020-03-05 16:00 ET
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular Lymphoma
2020-03-03 12:00 ET
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results
2020-02-28 12:30 ET
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2019 Financial Results and Business Update
2020-01-16 12:30 ET
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
2020-01-10 12:30 ET
TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-23 12:30 ET
TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor
2019-12-09 13:00 ET
TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition
2019-12-08 14:00 ET
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
2019-12-06 12:30 ET
TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition
2019-11-18 12:30 ET
TG Therapeutics to Present at the Jefferies London Healthcare Conference
2019-11-12 12:34 ET
TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
2019-11-08 12:30 ET
TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update
2019-11-06 14:15 ET
TG Therapeutics Announces Triple Combination Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition
2019-10-28 11:00 ET
TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma
2019-10-02 11:30 ET
TG Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
2019-09-30 11:30 ET
TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in Blood
2019-09-23 11:30 ET
TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
2019-09-20 11:30 ET
TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
2019-09-12 11:30 ET
TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
2019-04-15 11:30 ET
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma
2019-04-05 11:30 ET
TG Therapeutics to Present at the 18th Annual Needham Healthcare Conference
2019-04-01 12:30 ET
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
2019-03-29 20:00 ET
TG Therapeutics to Present Interim Data from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the Upcoming 2019 AACR Annual Meeting
2019-03-12 12:00 ET
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting
2019-03-11 07:26 ET
TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference
2019-03-08 12:30 ET
TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials

SEC forms

Show financial reports only

SEC form 8
2025-05-05 11:31 ET
TG Therapeutics reported for 2025 q1
SEC form 8
2025-05-05 11:31 ET
TG Therapeutics published news for 2025 q1
SEC form 10
2025-03-03 16:02 ET
TG Therapeutics reported for 2024 q4
SEC form 8
2025-03-03 07:19 ET
TG Therapeutics reported for 2024 q4
SEC form 8
2025-03-03 07:19 ET
TG Therapeutics published news for 2024 q4
SEC form 10
2025-03-03 00:00 ET
TG Therapeutics reported for 2024 q4
SEC form 10
2024-11-07 16:33 ET
TG Therapeutics reported for 2024 q3
SEC form 8
2024-11-04 07:19 ET
TG Therapeutics published news for 2024 q3
SEC form 8
2024-11-04 07:19 ET
TG Therapeutics published news for 2024 q3
SEC form 10
2024-08-09 16:03 ET
TG Therapeutics reported for 2024 q2
SEC form 10
2024-08-09 00:00 ET
TG Therapeutics reported for 2024 q2
SEC form 10
2024-05-06 00:00 ET
TG Therapeutics reported for 2024 q1
SEC form 8
2024-05-01 07:05 ET
TG Therapeutics reported for 2024 q1
SEC form 8
2024-05-01 07:05 ET
TG Therapeutics published news for 2024 q1
SEC form 10
2024-02-29 17:23 ET
TG Therapeutics reported for 2023 q4
SEC form 10
2024-02-29 00:00 ET
TG Therapeutics reported for 2023 q4
SEC form 8
2024-02-28 07:24 ET
TG Therapeutics published news for 2023 q4
SEC form 8
2024-02-28 07:24 ET
TG Therapeutics reported for 2023 q4
SEC form 10
2023-11-06 00:00 ET
TG Therapeutics published news for 2023 q3
SEC form 8
2023-11-01 07:33 ET
TG Therapeutics reported for 2023 q3
SEC form 10
2023-08-04 00:00 ET
TG Therapeutics reported for 2023 q2
SEC form 6
2023-08-01 07:29 ET
TG Therapeutics reported for 2023 q2
SEC form 6
2023-06-15 16:30 ET
TG Therapeutics published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
TG Therapeutics reported for 2023 q1
SEC form 8
2023-05-01 00:00 ET
TG Therapeutics reported for 2023 q1
SEC form 10
2023-03-01 17:21 ET
TG Therapeutics reported for 2022 q4
SEC form 10
2023-03-01 00:00 ET
TG Therapeutics reported for 2022 q4
SEC form 6
2023-02-28 07:33 ET
TG Therapeutics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
TG Therapeutics reported for 2022 q4
SEC form 6
2022-12-28 16:30 ET
TG Therapeutics published news for 2022 q3
SEC form 6
2022-11-10 07:38 ET
TG Therapeutics reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
TG Therapeutics reported for 2022 q3
SEC form 10
2022-11-09 16:30 ET
TG Therapeutics reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
TG Therapeutics reported for 2022 q3
SEC form 10
2022-08-09 16:01 ET
TG Therapeutics reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
TG Therapeutics reported for 2022 q2
SEC form 6
2022-08-08 07:37 ET
TG Therapeutics published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
TG Therapeutics reported for 2022 q2
SEC form 6
2022-06-23 16:31 ET
TG Therapeutics published news for 2022 q1
SEC form 10
2022-05-10 16:31 ET
TG Therapeutics reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
TG Therapeutics reported for 2022 q1
SEC form 6
2022-04-29 16:06 ET
TG Therapeutics published news for 2022 q1
SEC form 6
2022-04-18 07:30 ET
TG Therapeutics published news for 2022 q1
SEC form 10
2022-03-01 17:20 ET
TG Therapeutics published news for 2021 q4
SEC form 6
2022-03-01 08:15 ET
TG Therapeutics published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
TG Therapeutics published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
TG Therapeutics published news for 2021 q4
SEC form 6
2022-01-27 10:01 ET
TG Therapeutics published news for 2021 q4
SEC form 6
2022-01-04 07:39 ET
TG Therapeutics published news for 2021 q4
SEC form 6
2021-11-30 07:59 ET
TG Therapeutics published news for 2021 q3
SEC form 10
2021-11-08 16:16 ET
TG Therapeutics published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
TG Therapeutics published news for 2021 q3
SEC form 6
2021-11-04 07:27 ET
TG Therapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
TG Therapeutics published news for 2021 q3
SEC form 10
2021-08-06 17:01 ET
TG Therapeutics published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
TG Therapeutics published news for 2021 q2
SEC form 6
2021-08-02 07:12 ET
TG Therapeutics published news for 2021 q2
SEC form 8
2021-08-02 00:00 ET
TG Therapeutics published news for 2021 q2
SEC form 6
2021-06-22 18:16 ET
TG Therapeutics published news for 2021 q1
SEC form 6
2021-06-21 17:29 ET
TG Therapeutics published news for 2021 q1
SEC form 10
2021-05-10 17:02 ET
TG Therapeutics published news for 2021 q1
SEC form 6
2021-05-10 07:23 ET
TG Therapeutics published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
TG Therapeutics published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
TG Therapeutics published news for 2021 q1
SEC form 6
2021-04-30 16:01 ET
TG Therapeutics published news for 2021 q1
SEC form 6
2021-04-20 17:00 ET
TG Therapeutics published news for 2021 q1
SEC form 6
2021-04-16 07:53 ET
TG Therapeutics published news for 2021 q1
SEC form 6
2021-04-13 16:30 ET
TG Therapeutics published news for 2021 q1
SEC form 6
2021-03-02 07:07 ET
TG Therapeutics published news for 2020 q4
SEC form 10
2021-03-01 16:02 ET
TG Therapeutics published news for 2020 q4
SEC form 6
2021-02-08 07:01 ET
TG Therapeutics published news for 2020 q4
SEC form 6
2020-12-16 16:16 ET
TG Therapeutics published news for 2020 q3
SEC form 6
2020-12-10 07:50 ET
TG Therapeutics published news for 2020 q3
SEC form 6
2020-12-08 08:00 ET
TG Therapeutics published news for 2020 q3
SEC form 6
2020-11-09 17:29 ET
TG Therapeutics published news for 2020 q3
SEC form 6
2020-11-09 17:25 ET
TG Therapeutics published news for 2020 q3
SEC form 10
2020-11-09 17:04 ET
TG Therapeutics published news for 2020 q3
SEC form 6
2020-11-04 20:50 ET
TG Therapeutics published news for 2020 q3